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Abstract
Background: Severe aortic stenosis (AS) is a common, serious valve disease in which no effective medical therapy
is available and, if not treated by intervention, has a 5-year survival of only 40–60%. Despite the availability of
guidelines supporting the effective use of surgical aortic valve replacement (SAVR) or transcatheter aortic valve
implantation (TAVI) to treat the majority of these patients, adherence to these guidelines in clinical practice is still
unsatisfactory. Several recent studies have emphasised the necessity for improved communication between
multidisciplinary teams, with the aim to ensure that severe AS patients receive appropriate treatment.
Methods/design: IMPULSE is a prospective, multicentre, European registry designed to gather data over 12 months
on the treatment decisions made by referring physicians for patients newly diagnosed with severe AS. Each patient
has a follow-up of 3 months. The study will consist of two observational phases to assess the appropriateness and
rate of referral based on current guidelines prior to and after an interventional phase aiming to determine whether
a simple quality of care intervention improves patient management.
Discussion: Data will be analysed firstly, to determine the appropriateness of treatment decisions for the
management of severe AS in current European clinical practice, and secondly, to evaluate the effectiveness
of facilitated data relay from a designated echocardiography department nurse to the referring physician
early after diagnosis in improving quality of care. Additionally, variables will be identified that are associated
with inappropriate decision-making. Collectively, the aim will be to design a clinical pathway that will improve
the timely management of patients with newly diagnosed severe AS.
Keywords: Quality of care, Aortic stenosis, Transcatheter aortic valve implantation, Surgical aortic valve replacement,
Facilitated data relay
Background
Aortic stenosis (AS) is a common, serious valve disease
with a prevalence that increases with age, affecting
approximately 0.2% of patients aged 50–59, 1.3% of
patients aged 60–69, 3.9% of patients aged 70–79, and
9.8% of patients aged 80–89 [1]. Of those aged over
75 years in Europe and North America, 3.4% have AS
that is classed as severe [2], defined as a maximum jet
velocity (Vmax) ≥4 m/s, an aortic valve area (AVA)
≤1.0 cm2, or a transvalvular pressure gradient ≥40 mmHg
[3]. No effective medical treatment is available and if not
treated by intervention (surgical aortic valve replacement
(SAVR) or transcatheter aortic valve implantation (TAVI)),
severe AS is associated with a rapid physical decline
and a high rate of cardiac death within 3 years of symptom
onset [4].
The standard means for diagnosis of severe AS is trans-
thoracic echocardiography [5, 6]. ESC and ACC/AHA
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guidelines for subsequent management recommend that
asymptomatic patients receive serial clinical assessment
and an annual echocardiogram [3, 7]. Intervention (SAVR
or TAVI) is indicated when patients develop symptoms or,
if asymptomatic, when left ventricular ejection fraction
(LVEF) is <50%.
Though SAVR significantly increases life expectancy
and improves quality of life [8], a large proportion of pa-
tients with valvular disease have comorbid conditions that
would place them at high risk during a surgical procedure.
These factors include advanced age, poor LVEF, renal dis-
ease, and chronic obstructive pulmonary disease [9–12].
TAVI should be considered as an alternative in patients
for whom surgery is contraindicated or estimated at high
surgical risk, and data that are more recent suggest that
TAVI may also be beneficial in intermediate-risk patients
[13–16].
Despite the clear guidelines outlining the suitability
and timing of these interventions [3, 7], several studies
have reported non-adherence in clinical practice, with
disparity between current scientific recommendations
and treatment decisions estimated to occur in between
23 and 42% of AS patients [11, 17–19]. However, these
studies of non-adherence in clinical practice mostly pre-
date the availability of TAVI. Given the strong association
of AS with short-term mortality, results showing inappro-
priate delay could highlight a need for improvement in the
quality of care.
The main aims of the present study are firstly, to assess
the rate and reasons for potential disparities between the
proportion of patients diagnosed with severe AS and those
actually treated, and secondly, to evaluate the impact of a
simple, early, quality improvement intervention (in the
form of facilitated data relay from a dedicated centre co-
ordinator) to narrow the gap. Using this information, the
aim of the study is to establish a clinical pathway to ensure
adequate follow-up and management of AS patients.
Methods/Design
IMPULSE is a prospective, international, multi-centre,
registry-based cohort study evaluating the quality of care
for patients with severe AS. The study combines obser-
vational and interventional elements in order to assess
the current state of care and the potential for a simple
intervention to improve quality. The aim is to enrol a
study population of over 2500 patients consecutively
across 25 centres in 10 European countries. The registry
is established in accordance with the declaration of
Helsinki (1964), and prior ethical agreements have been
obtained from the appropriate ethics committee for each
site. Patients are required to provide informed consent
prior to enrolment, and data are collected by a co-
ordinating study nurse in the form of electronic case
report forms (eCRFs).
Site selection
Only sites able to offer a comprehensive range of the cur-
rently available AS treatments will participate in the regis-
try. A study nurse is employed at the centres specifically
to monitor echocardiography results and to communicate
with the referring physician (RP) in a structured manner.
Patient selection
To be eligible for inclusion in the registry, patients must
be aged 18 or over and diagnosed with severe AS by echo-
cardiography. Severe AS is defined as having an aortic
valve meeting at least one of the following criteria: 1)
AVA < 1 cm2, 2) valve area index <0.6 cm/m2, 3) Vmax >
4.0 m/s, 4) mean transvalvular gradient > 40 mm Hg. All
patients with previous AVR, or AS not considered severe
according to the aforementioned criteria, will be excluded
from the registry. Patients will be excluded if they have
cognitive impairment that may limit their understanding
of the factors involved in study participation, including
the consent process. Enrolment will be consecutive.
Data collection
All data are entered into the eCRF (s4trials, Berlin,
Germany) and signed by the study nurse at the earliest
opportunity, using registry identification numbers ra-
ther than names to protect identity. Automatic checks
for plausibility and completeness are performed, and all
data sets will be examined for irregularities by the data
manager.
For each patient, baseline characteristics (including
symptoms, co-morbidities, frailty, and EuroSCORE
values), echocardiogram findings, and contact details
will be documented at the point of individual study
enrolment (where enrolment is defined as the time of
informed consent directly after echocardiography-based
diagnosis of severe AS). In addition, symptom status,
co-morbidity, frailty, and eligibility for different treat-
ment options (pharmaceutical management, SAVR, or
TAVI) will be collected by the study nurse.
The main follow-up will be performed for all patients
via a structured telephone call or contact with the RP
3 months after the date of each individual enrolment
(i.e. a patient diagnosed and enrolled on day 9 will be
followed-up at 3 months + 9 days). Follow-up data will
include vital status, emergency admissions, referrals, and
treatment since enrolment, as well as the sub-specialty
of the healthcare professional responsible for making
such a decision. Vital status at one year will be also col-
lected via chart review and contact of the RP.
For the subset of patients included in the interven-
tional phase only (see definitions below), data regarding
the vital status of a particular patient, and the treatment
plans or referral intentions of the RP (active decision
not to treat, watchful waiting, conservative management,
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balloon aortic valvuloplasty (BAV), SAVR, or TAVI) will
be obtained 1 week after the date of each individual en-
rolment. Watchful waiting is defined as the scheduling
of a further outpatient assessment, stress echocardiography,
exercise testing, transoesophageal echocardiography,
catheterisation, computed tomography, or referral to a
valve service or other clinician. Conservative manage-
ment is defined as medical therapy only.
Study phases and interventions
Study duration will be 15 months at each participating
site, starting from the point of first patient enrolment.
This study period is divided into 3 distinct phases (Fig. 1)
with 3 different patient groups, as follows:
 Observational phase 1: Includes all patients enrolled
between month 0 and month 3. No contact is made
with the RP regarding the IMPULSE study until
follow-up at 3 months, at which time details on
medical treatment in the interim are collected.
 Interventional phase: Includes all patients enrolled
between month 4 and month 9. The RP is contacted
by the study nurse 1 week after individual patient
enrolment and advised that their patient has been
diagnosed with severe AS (facilitated data relay) and
consented to participation in the present quality
improvement study. The RP is asked to provide
details on the vital status of the patient and their
intended treatment plans at this point. They are
then contacted again at 3 months; at which time,
details on treatment in the interim are collected.
 Observational phase 2: Includes all patients enrolled
between months 10 and 12. This phase is carried out
as the observational phase 1 to adjust for potential
seasonal variation in the clinical presentation of the
patients and with the intention of detecting any
persisting influence of the interventional phase on
the subsequent treatment decisions made by RPs.
Outcome measures
The primary outcome measure is the rate of SAVR or
TAVI by the RP at 3-month follow-up in each of the 3
phases. Secondary outcome measures are as follows: 1)
the rate of referral for exercise testing or stress echocar-
diography by the RP at 3 month follow-up, 2) time to
next out-patient appointment or clinical review, 3) type
of treatment plan selected (active decision not to treat,
watchful waiting, conservative management, BAV, SAVR,
or TAVI), 4) the appropriateness of treatment decisions
made in collaboration with the valve specialist, and 5)
survival outcome one year post-diagnosis.
Statistics
We estimated that we would be able to capture a mean
of 100 consecutive patients per site, 25 during the first
observational phase, 50 in the interventional phase and
another 25 during the second observational phase. The
final sample size estimate was based on the aim to involve
25 sites in different countries and health care systems
across Europe and to ask them to enrol patients through-
out a year.
Intention-to-treat analysis including all enrolled patients
will be carried out. Descriptive summaries will be used to
present the collected evaluation data. For categorical
variables (e.g. gender) frequency distributions will be
given. Statistical significance will be determined using a
chi-squared or a Fisher’s exact test. For numeric variables
(e.g. patient age) minimum, maximum, mean, median,
Fig. 1 Timeline of the IMPULSE Study. This timeline refers to the study progression at each individual site, starting from enrolment of the first
patient at that site. Each bar is indicative of the upper and lower limits of the period within which any one event occurred. Accordingly, follow-up and
interventional call timings are relative to the point of individual patient enrolment (i.e. a patient diagnosed and enrolled on day 9 will be followed-up
at 3 months + 9 days). FPE: First Patient Enrolled at the particular site; RP: Referring Physician
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and standard deviation will be calculated. Statistical sig-
nificance will be determined using a student’s t-test in the
case of normally distributed data, or a Mann–Whitney U-
test for non-normally distributed data. Linearized rates
and actuarial probability statistics may be used where
appropriate for adverse event reporting. Kaplan-Meier
analysis will be performed for survival outcomes and,
where appropriate, for adverse event outcomes.
Discussion
In the present multinational, registry-based, prospective
analysis, we aim to gather data on the appropriateness of
current follow-up and referral after diagnosis of severe
AS in Europe, and further establish the impact of a sim-
ple quality improvement intervention on this practice.
Using the considerable quantity of information gathered,
this should allow us to establish an evidence-based clinical
pathway for the effective management of patients with
severe AS.
Current practice
In the first observational phase, the appropriateness of
treatment decisions for the management of severe AS in
current European clinical practice will be evaluated, and
the scale of any deficit quantified. This is following several
previous studies that have revealed consistently low rates
of appropriate management in a considerable proportion
of AS patients. In 2003, the large-scale Euro Heart Survey
showed that 31.8% of patients with severe, symptomatic,
single-valvular heart disease did not receive an interven-
tion, and that surgery was denied in one third of AS symp-
tomatic patients [20]. Later, in 2010, Freed et al. reported
from a small study in 106 patients, that 69% of severe AS
patients were not referred for valve replacement, of which
42% were symptomatic and 21% had LVEF <50%; there-
fore making them eligible for consideration under ACC/
AHA guidelines [18]. More recent data have reported
similar failings in monitoring valve disease, with a large
but retrospective series identifying that only 59% of pa-
tients with moderate-severe left-sided valve disease re-
ceived follow-up echocardiography within 60 days of the
time recommended in existing guidelines [17]. Therefore,
a deficit between eligibility and adequate management has
been documented consistently, regardless of period, coun-
try, disease severity, or available treatment.
A combination of patient and physician-based factors
has been proposed to explain the gap between guidelines
and clinical practice [17]. Clinicians in the Euro Heart
Survey reported advanced age, severe left ventricular dys-
function, recent myocardial infarction, severe coronary
disease, prior neurological disease, and a decrease in
symptoms under medical treatment as justifications for
not referring a patient for SAVR [20] but several of these
potential reasons are highly debatable. Additionally, Freed
et al. found that the lack of referral for SAVR or TAVI in
symptomatic patients was mainly due to failure of the
treating physician to attribute symptoms to AS (29%),
followed by an elevated surgical risk (15%), despite 40% of
the latter patients having low EuroSCORE parameters
[18]. Furthermore, existing methods for determining
surgical risk (such as the logistic EuroSCORE model and
on-line STS Risk Calculator) have many pitfalls and limi-
tations, and appear not to reliably predict the true likeli-
hood of mortality in all patients; particularly those
undergoing TAVI [21]. Thus, a RP with poor knowledge
of the limitations of current assessment tools in valvular
heart disease may erroneously prevent eligible patients
from undergoing lifesaving intervention.
Taken together, these results suggest that appropriate
medical attention may be delayed or withheld in a signifi-
cant proportion of patients due to poor decisions made by
RPs acting independently rather than in the environment
of a ‘heart team’ discussion. Observational phase 1 of the
present study will supply further insight into the validity
of this assumption in contemporary practice, and provide
data on the type of physician currently responsible for
making treatment decisions. Furthermore, justifications
for non-referral will be collected to identify variables asso-
ciated with inadequate treatment decisions. This may be
useful for educating physicians and improving appropri-
ateness of future treatment.
Quality improvement intervention
Several different strategies for quality improvement have
been suggested to enhance patient care. The need for a
well-organised valve service to improve monitoring,
evaluation, and timing of intervention for patients with
AS has been highlighted in several recent publications
[22–24]. A key element of this valve service is to ensure
effective, multidisciplinary communication between team
members, including echocardiographers and clinicians,
co-ordinators, interventional cardiologists, and cardio-
thoracic surgeons [23]. This should, in theory, maximise
the number of patients receiving the appropriate ther-
apy, increase referral rates for intervention and thereby
minimise morbidity and mortality. However, with cost
effectiveness always a key concern, healthcare institu-
tions favour economical interventions with a clear busi-
ness case [22].
A previous study by Taggu et al. described the positive
outcomes of a quality of care intervention for patients
with valvular disease, reporting that the agreement be-
tween clinical follow-up and best practice guidelines rose
by 51% following the establishment of sonographer-led
valve clinics for patients with stable valve disease [24].
This highlights the capacity for improvement in the care
of patients with valvular disease, although main focus
was on monitoring rather than on intervening. In the
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interventional phase of the present study, the effect of
employing a single, dedicated echocardiography clinic
nurse to notify the RP of a finding of severe AS will be
evaluated. Outcomes such as referral rate will be com-
pared to those seen in observational phase 1 to detect any
improvements. This type of intervention via a phone call
or other non-automated method is known as facilitated
relay of patient data [25]. In a previous, large systematic
review of quality improvement strategies in the care of
hypertensive patients, implementation of simple facilitated
data relay was shown to reduce systolic and diastolic
blood pressure by a median of 8.0 and 1.8 mmHg, respect-
ively, and result in 25.1% more patients attaining systolic
blood pressure within their target range [26]. This sug-
gests that such an intervention can have a substantial im-
pact on patient care, though it has never been tested in
the context of severe AS. Should the present study dem-
onstrate significant improvements in the appropriateness
of patient referral for timely and appropriate intervention
under the facilitated data relay intervention, implementa-
tion would be simple and low-cost, making it an attractive
strategy for improving quality of care.
For the third phase of the present study, the facili-
tated relay of diagnosis will be stopped and its legacy
effect on patient management evaluated. This will indi-
cate whether the intervention was efficient at changing
the behaviour of the RPs and indicate the potential for
short interventions to be effective in the longer-term.
Potential limitations
Firstly, the largely observational nature of the IMPULSE
study means that investigators will have little control
over the characteristics of the severe AS patients en-
rolled. Considering that 3 distinct populations will be
used for different phases of the study, this may result in
an uneven distribution of treatment decisions between
phase groups. Accordingly, the appropriateness of RP
decisions may reflect mistakes due to more challenging
patient variables, rather than active deviations from
guidelines. However, this is unavoidable if a snapshot of
real-world practice is to be obtained, and the high pa-
tient numbers planned for enrolment over a reasonable
time period (minimum 3 months) should accommodate
for such imbalances.
The study does not involve an investigation into the con-
tribution of patient/family preferences to the treatment
decision-making process. It will therefore not be possible
to exclude this important variable from the assessment of
the appropriateness of the RP’s decision. In the present
analysis we will focus on evaluating guideline adherence,
with future work potentially delving into the underlying
reasons for RPs deviating from the recommendations.
The relatively short study duration means that guide-
line adherence will only be evaluated up to 3 months
post-diagnosis. This means that long-term consequences
of appropriate/inappropriate management are beyond
the scope of the current study. Additionally, phase 3 will
only be suitable for assessing the short-term legacy of
the quality of care intervention, and further studies will
be necessary to establish any longer-term effects. How-
ever, for providing an initial view into the efficacy of
facilitated data relay to improve initial care decisions in
severe AS patients, 3 month follow-up is sufficient.
Lastly, during the facilitated data relay intervention
stage, the physician is not only informed of diagnosis
outcomes, but also of their patient’s participation in a
study. This may result in a feeling that their professional
capacity is being evaluated, prompting more conscien-
tious decision-making. Although clearly an advantage
for study participants, this may result in over-estimation
of the effect the quality of care intervention would have
under real-world, non-study conditions. However, in
order to comply with ethical guidelines, such a notifica-
tion is unavoidable.
Conclusion
This large-cohort, prospective, multinational, registry-
based study will generate important data regarding current
rates of good practice guideline adherence in patients diag-
nosed with severe AS, and the potential for a simple quality
of care intervention in the form of facilitated data relay to
improve this. This information will be used to establish a
clinical pathway that can be applied to healthcare services
to ensure appropriate patient management. Accordingly,
IMPULSE may contribute to reductions in morbidity and
mortality rates associated with the referral gap in severe
AS patients.
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